Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - Cartesian Therapeutics, Inc. reported a quarterly loss of $0.69 per share, which was better than the Zacks Consensus Estimate of a loss of $0.78, and a significant improvement from a loss of $2.40 per share a year ago, indicating an earnings surprise of 11.54% [1] Financial Performance - The company posted revenues of $0.39 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 93.55%, and a decline from $6.55 million in revenues from the same quarter last year [2] - Over the last four quarters, Cartesian Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Cartesian Therapeutics shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 24.3% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.73 on revenues of $6 million, and for the current fiscal year, it is -$4.54 on revenues of $43.29 million [7] - The estimate revisions trend for Cartesian Therapeutics is mixed, and future stock movements will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Cartesian Therapeutics belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8]